AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Neutral Stance on Xoma Amid Strategic Acquisitions and Uncertain Growth Outlook
ByAinvest
Wednesday, Aug 13, 2025 5:24 pm ET1min read
Xoma maintains a Hold rating from TD Cowen analyst Phil Nadeau due to stable financial performance and strategic acquisitions. While the company's recent deals add potential future revenue streams, the immediate impact on profitability and growth is uncertain. Nadeau's 3-star rating is based on a 2.7% average return and 40.87% success rate in the Healthcare sector.
XOMA Royalty (NASDAQ: XOMA) has reported its second quarter and year-to-date (YTD) financial results for 2025, showcasing robust growth and strategic acquisitions. The company reported $29.6 million in royalties and milestones in the first half of 2025, including $11.7 million in the second quarter. This performance is driven by increased royalties from VABYSMO and OJEMDA, as well as significant pipeline advancements.The company's net income for the second quarter was $9.2 million, up from $7.4 million in the second quarter of 2024. Total income/revenue for the quarter was $13.1 million, compared to $11.1 million in the same period last year. XOMA ended the quarter with $78.5 million in cash and cash equivalents, reflecting strong financial health.
Strategic acquisitions have been a key driver of XOMA's growth. The company acquired Turnstone Biologics, LAVA Therapeutics, and HilleVax, and purchased mezagitamab royalty rights from BioInvent for $20 million. These acquisitions expand XOMA's portfolio and create potential future revenue streams.
Pipeline advancements are also contributing to XOMA's growth. Rezolute completed enrollment in its Phase 3 sunRIZE study for ersodetug, and Takeda initiated a Phase 3 trial for mezagitamab. Additionally, Zevra submitted an MAA to the EMA for arimoclomol. These developments position XOMA for potential future royalty streams.
Despite the strong financial performance, XOMA faces uncertainty regarding the immediate impact of its recent deals on profitability and growth. TD Cowen analyst Phil Nadeau maintains a Hold rating for XOMA, citing stable financial performance and strategic acquisitions. Nadeau's rating is based on a 2.7% average return and a 40.87% success rate in the Healthcare sector.
References:
[1] https://www.stocktitan.net/news/XOMA/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-vomm2z8bess1.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet